EyeGate is developing and commercializing products for treating diseases and disorders of the eye. The Companyâs products are based on two proprietary platform technologies: EyeGateâs first platform is based on a cross-linked thiolated carboxymethyl hyaluronic acid (âCMHA-Sâ), a modified form of the natural polymer hyaluronic acid (âHAâ), which is a gel that possesses unique physical and chemical properties including hydration and healing when applied to the ocular surface. The ability of CMHA-S to protect and adhere longer to the ocular surface, and resist degradation makes it well-suited for treating various ocular surface injuries. EGP-437, EyeGateâs second product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGateâs proprietary innovative drug delivery system, the EyeGate II Delivery System. EGP-437 is currently in trials for the treatment of uveitis and pain and inflammation following cataract surgery. EyeGate has granted a subsidiary of Valeant Pharmaceuticals an exclusive worldwide license to the product in these indications. Source
No articles found.
iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solut...
iCAD, Inc. an industry-leading provider of adva...
Nature is full of untapped potential. Microbes are a proven but underused resource...
Nature is full of untapped potential. Microbes ...
DBV Technologies is developing ViaskinÂŽ, an investigational proprietary technolog...
DBV Technologies is developing ViaskinÂŽ, an in...
Founded in 2006 and headquartered in San Diego, Adamis (ADMP) is a specialty bioph...
Founded in 2006 and headquartered in San Diego,...
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...
Trovagene is a clinical-stage, oncology therape...
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...
Galapagos develops therapies with proprietary, ...
Join the National Investor Network and get the latest information with your interests in mind.